ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Arcturus Therapeutics is a commercial messenger RNA (mRNA) medicines company focused on infectious disease vaccines and rare diseases. The company recently transitioned to a commercial stage following the approval of its self-amplifying mRNA (sa-mRNA) vaccine, KOSTAIVE (ARCT-154), in Japan (2023) and the European Union (February 2025). Key partnerships include a global collaboration with CSL Seqirus for vaccine development and a cost-reimbursement contract with BARDA for pandemic influenza vaccine development.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 23% ($8.6 million) compared to Q1 2024. This was primarily driven by a $6.9 million decrease in collaboration revenue from CSL Seqirus due to smaller milestone achievements and reduced amortization as KOSTAIVE transitions to commercialization. Grant revenue from BARDA also decreased by $1.5 million.
• Expense Reduction: Total operating expenses decreased by 32% ($22.2 million). Research and Development (R&D) expenses dropped 35% to $34.9 million, largely due to reduced manufacturing costs for LUNAR-COVID and LUNAR-FLU programs. General and Administrative (G&A) expenses fell 24% to $11.3 million, primarily due to lower share-based compensation.
• Improved Net Loss: Net loss improved by $12.7 million year-over-year, reflecting the significant reduction in operating expenses.
• Debt Activity: The company drew down $15.0 million on its Wells Fargo revolving credit facility in March 2025, which was subsequently repaid in April 2025. This resulted in a $15.0 million long-term debt balance on the March 31 balance sheet.
• Cash Flow: Net cash used in operating activities increased significantly to $35.1 million (from $5.6 million in Q1 2024), driven by a $15.6 million increase in accounts receivable due to invoicing timing and a $15.5 million unfavorable change in accrued liabilities and accounts payable.

Guidance, Outlook, and Risks

• Commercial Milestones: KOSTAIVE received EU marketing authorization in February 2025. The company achieved an $8.0 million milestone related to EU approval and a $7.0 million development milestone in Q1 2025.
• Pipeline Progress:
  • LUNAR-CF (ARCT-032): Phase 2 multiple ascending dose study initiated in the U.S. in December 2024.
  • LUNAR-OTC (ARCT-810): Phase 2 study expanded to the U.S.; first participant dosed in December 2024.
  • LUNAR-H5N1 (ARCT-2304): Phase 1 trial recruitment completed in April 2025; received FDA Fast Track Designation.
• Liquidity: Management believes current cash resources ($273.8 million) are sufficient to fund operations for at least the next 12 months. Future funding may be required via equity/debt financing or partnership milestones.
• Material Weakness in Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to Information Technology General Controls (ITGCs), specifically regarding user access, program change management, and IT operations. This weakness existed as of March 31, 2025, and remediation is ongoing with an expected completion in fiscal year 2025.
• Risks: Risks include the ability to achieve future milestones under the CSL Seqirus agreement, regulatory approval timelines, and the need for additional capital if milestones are not met or costs exceed forecasts.

Investor Verification Checklist

• Verify the timing and amount of future milestone payments from CSL Seqirus, particularly those tied to commercial sales of KOSTAIVE in the EU and Japan.
• Monitor the progress of the remediation plan for the material weakness in IT general controls to ensure financial reporting reliability.
• Track the enrollment and safety data from the Phase 2 trials for ARCT-032 (Cystic Fibrosis) and ARCT-810 (OTC deficiency).
• Assess the impact of the $15.6 million increase in accounts receivable on future cash collections.
• Review the status of the BARDA contract, noting $36.1 million in remaining available funding as of March 31, 2025.